Siemens Healthcare BNP (8-type Natriuretic Peptide) 500 Test kit 02816634 100 Test 02816138 10309045, 10309044 028 Intended Use For in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA Centaur and ADVIA Centaur XP systems. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS), this test, in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure.
Publicado el 19 de diciembre de 2012 · Inicio del retiro: 14 de noviembre de 2012
Resumen
FDA registra el retiro Z-0506-2013 de dispositivos médicos de Clase II, publicado el 19 de diciembre de 2012 e iniciado el 14 de noviembre de 2012. Empresa responsable: Siemens Healthcare Diagnostics, Inc; Estado: Finalizado; Cantidad reportada: 100 test=24291 and 500 test= 9679; Lote: All lot codes. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Operating range of the ADVIA Centaur systems is 18®C to 30®C (64.4®F to 86.0®F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Siemens Healthcare Diagnostics, Inc
- Distribuidor
- Worldwide Distribution - USA (nationwide) and Internationally to the following countries: Argentina Australia Austria Azerbaijan Belgium Bosnia Herzeg. Brazil Canada Chile COLOMBIA Croatia Czech Republic Denmark Egypt Estonia Finland France Germany Greece Hong Kong Hungary Iceland India Indonesia Iran Ireland Italy Japan Kazakhstan Latvia Lithuania Malaysia Mexico Netherlands New Caledonia Norway Oman P.R. China Philippines Poland Portugal Qatar Rep. of Yemen Republic Korea Reunion Romania Russian Fed. Saudi Arabia Serbia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Thailand Turkey U.A.E. United Kingdom Uruguay Vietnam
- Lote
- All lot codes
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDASiemens ADVIA Centaur Folate 100 test kit-for IVD of folate in serum or red blood cells SMN:1031030829 de enero de 2020
- FDASiemensADVIA Centaur aTG (500 test kit) Siemens Material Number (SMN): 104923998 de mayo de 2019
- FDAAtellica IM aTG (500 test kit) Siemens Material Number (SMN): 109954628 de mayo de 2019
- FDASiemens Atellica IM aTG (100 test kit) Siemens Material Number (SMN): 109954618 de mayo de 2019
- FDAWANG Transbronchial Aspiration Needles Cat. No. MW-221, WANG Cytology Needles, Central or Peripheral Regions,19 de diciembre de 2012
- FDASiemens Healthcare BR Assay for CA 27.29 250 Test Kits 03896216 50 Test Kit 02419937 Ref Kit (US only)19 de diciembre de 2012
Preguntas sobre este retiro
¿Siemens Healthcare BNP (8-type Natriuretic Peptide) 500 Test kit 02816634 100 Test 02816138 10309045, 10309044 028 Intended Use For in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA Centaur and ADVIA Centaur XP systems. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS), this test, in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure. fue retirado del mercado?
Sí. FDA publicó el retiro Z-0506-2013 el 19 de diciembre de 2012. Peligro reportado: Operating range of the ADVIA Centaur systems is 18®C to 30®C (64.4®F to 86.0®F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter